Japanese authorities conducted an investigation on Saturday at the Osaka factory of Kobayashi Pharmaceutical after a beni-koji supplement produced there was linked to the hospitalization of over 100 people and five deaths.
Officials from the Ministry of Health, Labor and Welfare, along with Osaka government departments, entered the facility to examine potential issues related to the supplement’s production.
Kobayashi Pharmaceutical stated that it is investigating a suspected link between the products and kidney disease but did not disclose details about the ongoing investigation.
As of Thursday evening, 114 individuals had been hospitalized and five fatalities were reported after consuming the beni-koji supplements, which are marketed to help lower cholesterol levels.
In response to the incidents, the company has initiated a recall of the affected Beni-Koji products. The supplement contains Monascus purpureus, a red mold also used as a food coloring agent.
The Chinese Consumer Association has urged consumers to discontinue use of the affected products, expressing concern over the associated health risks.
Kobayashi Pharmaceutical, based in Osaka, could not be immediately reached for further comment regarding the situation.
The investigation may expand to other related locations as authorities continue to assess the safety and production practices of the company’s products.
Reference(s):
cgtn.com
